Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
15 Février 2025 - 3:04AM
Edgar (US Regulatory)
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under
the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement
on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.001 per share of Inhibikase Therapeutics, Inc.,
a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.
In evidence thereof, the undersigned,
being duly authorized, have executed this Joint Filing Agreement as of February 14, 2025.
| |
ADAR1 CAPITAL MANAGEMENT, LLC |
| |
|
| |
/s/ Daniel Schneeberger |
| |
Daniel Schneeberger |
| |
Manager |
| |
|
| |
ADAR1 CAPITAL MANAGEMENT GP, LLC |
| |
|
| |
/s/ Daniel Schneeberger |
| |
Daniel Schneeberger |
| |
Manager |
| |
|
| |
/s/ Daniel Schneeberger |
| |
Daniel Schneeberger, in his individual
capacity |
Inhibikase Therapeutics (NASDAQ:IKT)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Inhibikase Therapeutics (NASDAQ:IKT)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
